Patents by Inventor Lan Zheng

Lan Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOSENSING ELEMENT BASED ON SPECIFIC BINDING OF CBM AND CELLULOSE
    Publication number: 20230295584
    Abstract: Provided is a fusion protein for a biosensing element; the fusion protein includes glucose oxidase (GOD) and a carbohydrate-binding module (CBM); and the GOD is linked to the CBM by means of a linker peptide. The biosensing element specifically binds to cellulose based on CBM.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 21, 2023
    Inventors: Weili GONG, Yaohong MA, Lei CAI, Binglian WANG, Qingjun MENG, Qingai LIU, Lan ZHENG, Yan YANG, Junhui YANG, Yiwei LI, Jianguo SHI, Qingye HAN
  • Oral solid formulation of compound anti-tubercular drug and preparation method thereof
    Patent number: 9555003
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: January 31, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang
  • ORAL SOLID FORMULATION OF COMPOUND ANTI-TUBERCULAR DRUG AND PREPARATION METHOD THEREOF
    Publication number: 20140127294
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Application
    Filed: April 10, 2012
    Publication date: May 8, 2014
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang